(Q34004118)

30 July 2017

Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions (English)

1 reference

30 July 2017

1 reference

1 reference

Dirk Daelemans

2

0 references

Dominique Schols

object named as

Dominique Schols

10

0 references

Jan Balzarini

12

object named as

Jan Balzarini

1 reference

30 July 2017

Claire Bertaux

1

1 reference

30 July 2017

Laurent Meertens

3

1 reference

30 July 2017

Emmanuel G Cormier

4

1 reference

30 July 2017

John F Reinus

5

1 reference

30 July 2017

Willy J Peumans

6

1 reference

30 July 2017

Els J M Van Damme

7

1 reference

30 July 2017

Yasuhiro Igarashi

8

1 reference

30 July 2017

Toshikazu Oki

9

1 reference

30 July 2017

Tatjana Dragic

11

1 reference

30 July 2017

language of work or name

English

0 references

publication date

11 May 2007

1 reference

30 July 2017

1 reference

30 July 2017

366

1 reference

30 July 2017

40-50

1 reference

30 July 2017

1

1 reference

Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Microbicide drug candidates to prevent HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Early steps in O-linked glycosylation and clustered O-linked glycans of herpes simplex virus type 1 glycoprotein C: effects on glycoprotein properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

HIV entry and fusion inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Hepatitis C transmission -- where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Human respiratory syncytial virus surface glycoproteins F, G and SH form an oligomeric complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

In search of hepatitis C virus receptor(s).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

A general model for the surface glycoproteins of HIV and other retroviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Glycosylation of hepatitis C virus envelope proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Correlation between carbohydrate structures on the envelope glycoprotein gp120 of.HIV-1 and HIV-2 and syncytium inhibition with lectins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Pradimicin resistance of yeast is caused by a mutation of the putative N-glycosylation sites of osmosensor protein Sln1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Expression of DC-SIGN and DC-SIGNR on Human Sinusoidal Endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Transmission and epidemiology of HIV/AIDS: a global view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Complete replication of hepatitis C virus in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Basic amino acids as modulators of an O-linked glycosylation signal of the herpes simplex virus type 1 glycoprotein gC: functional roles in viral infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Characterization of functional hepatitis C virus envelope glycoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Evaluation of current approaches to inhibit HIV entry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

A role for carbohydrates in immune evasion in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Multiple glycosylated forms of the respiratory syncytial virus fusion protein are expressed in virus-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Novel anti-viral therapy: drugs that block HIV entry at different target sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Management of chronic hepatitis B and C in HIV-coinfected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Antiviral effects of glycosylation and glucose trimming inhibitors on human parainfluenza virus type 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Studies on the mode of antifungal action of pradimicin antibiotics. III. Spectrophotometric sequence analysis of the ternary complex formation of BMY-28864 with D-mannopyranoside and calcium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Leaves of the Orchid Twayblade (Listera ovata) Contain a Mannose-Specific Lectin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

A comparative study of mannose-binding lectins from the amaryllidaceae and alliaceae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Functional hepatitis C virus envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Robust hepatitis C virus infection in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.04.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2007.04.008

1 reference

30 July 2017

1 reference